GABAB Receptor Agonist Treatment for Methamphetamine-Induced Cognitive Impairment in Mice
Author Information
Author(s): Mizoguchi Hiroyuki, Yamada Kiyofumi
Primary Institution: Nagoya University
Hypothesis
Can baclofen, a GABAB receptor agonist, improve cognitive deficits induced by methamphetamine in mice?
Conclusion
Baclofen effectively ameliorated cognitive deficits in mice treated with methamphetamine, suggesting it may be a new treatment target for cognitive impairments in chronic meth users.
Supporting Evidence
- Baclofen improved object recognition memory and prepulse inhibition deficits in mice treated with methamphetamine.
- Repeated methamphetamine treatment caused long-lasting cognitive deficits in mice.
- GABAB receptors may be a new target for treating cognitive deficits in chronic meth users.
Takeaway
This study found that a medicine called baclofen can help mice remember things better after they have been given methamphetamine, which usually makes it hard for them to think.
Methodology
Mice were treated with methamphetamine and then given baclofen to assess its effects on cognitive functions like memory and sensorimotor gating.
Limitations
Further studies are needed to clarify the molecular mechanisms of baclofen's action.
Participant Demographics
Mice were used as the animal model for the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website